Metagenomi, Inc. (NASDAQ:MGX) Receives $16.67 Average PT from Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $16.67.

A number of research analysts have recently issued reports on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Metagenomi in a research report on Wednesday, November 20th. HC Wainwright lifted their price target on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th.

Institutional Investors Weigh In On Metagenomi

A number of large investors have recently made changes to their positions in MGX. Virtu Financial LLC acquired a new stake in Metagenomi during the 3rd quarter worth about $33,000. Geode Capital Management LLC lifted its holdings in shares of Metagenomi by 105.8% during the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after purchasing an additional 173,796 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Metagenomi by 209.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock valued at $296,000 after buying an additional 92,468 shares during the last quarter. Verition Fund Management LLC acquired a new position in Metagenomi in the 3rd quarter worth approximately $82,000. Finally, BNP Paribas Financial Markets raised its position in Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after buying an additional 7,256 shares during the last quarter.

Metagenomi Trading Down 4.5 %

MGX opened at $3.62 on Monday. The business’s 50-day moving average is $2.67 and its two-hundred day moving average is $3.01. Metagenomi has a 1 year low of $1.61 and a 1 year high of $12.74.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.